Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Gregory Russell Pond"'
Autor:
Lisa A. Kottschade, Gregory Russell Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J. Hauke, Brendan D. Curti, Sarah Schober, Mohammed M. Milhem, Matthew Stephen Block, Tina Hieken, Robert R. McWilliams
Publikováno v:
Clinical Cancer Research. :OF1-OF6
Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for a
Autor:
Robert R. McWilliams, Tina Hieken, Matthew Stephen Block, Mohammed M. Milhem, Sarah Schober, Brendan D. Curti, Ralph J. Hauke, Evidio Domingo-Musibay, Yousef Zakharia, Anthony J. Olszanski, Gregory Russell Pond, Lisa A. Kottschade
Purpose:Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0595386c15d26d6b914b03df28d04b14
https://doi.org/10.1158/1078-0432.c.6615932.v1
https://doi.org/10.1158/1078-0432.c.6615932.v1
Autor:
Robert R. McWilliams, Tina Hieken, Matthew Stephen Block, Mohammed M. Milhem, Sarah Schober, Brendan D. Curti, Ralph J. Hauke, Evidio Domingo-Musibay, Yousef Zakharia, Anthony J. Olszanski, Gregory Russell Pond, Lisa A. Kottschade
Grade 3+ Adverse Events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db1553aa09b4d3d031f053b9d0c7c97
https://doi.org/10.1158/1078-0432.22692632.v1
https://doi.org/10.1158/1078-0432.22692632.v1
Autor:
Srikala S. Sridhar, Nicholas Power, Rodney H. Breau, Susanna Y. Cheng, Gregory Russell Pond, Peter W. M. Chung, Ur Metser, Mark Norman Levine, Som D. Mukherjee
Publikováno v:
Journal of Clinical Oncology. 41:460-460
460 Background: Muscle invasive bladder cancer (MIBC) is an aggressive local disease where initial staging with conventional CT imaging is often suboptimal. To explore the role of PET-CT in both staging MIBC and assessing response to neoadjuvant chem
Autor:
Aly-Khan A. Lalani, Anand Swaminath, Gregory Russell Pond, Scott Carlyle Morgan, Arun Azad, William Chu, Eric Winquist, Anil Kapoor, Michael Bonert, Jonathan L. Bramson, Michael G. Surette, Christina M. Canil, Shankar Siva, Georg A. Bjarnason, Mark Norman Levine, Jim Wright, Sebastien J. Hotte
Publikováno v:
Journal of Clinical Oncology. 41:TPS750-TPS750
TPS398 Background: Randomized data from the interferon era demonstrated survival benefits of cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC). Results from SURTIME and CARMENA, conducted in the VEGF-targeted ther
Autor:
Talal El Zarif, Amin Nassar, Lijuan Jiang, Gregory Russell Pond, Tony Zhuang, Maud Velev, Andrew Warren Hahn, Sebastiano Buti, Pablo Álvarez, Rana R. McKay, Bruno Vincenzi, Edward El-Am, Gavin Hui, Jae-Lyun Lee, Tarek H. Mouhieddine, Matthew I. Milowsky, Harrison Matthews, Pedro C. Barata, Andrea B. Apolo, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 41:5-5
5 Background: Management options for patients (pts) with advanced (locally advanced or metastatic) PeCa are limited. The GSRGT assembled an international cohort of pts with advanced PeCa treated with ICI to evaluate toxicity and clinical outcomes. Me
Autor:
Sarah J. Mah, Jonathan Bellini, Lucy Zhao, Julie My Van Nguyen, Clare J. Reade, Waldo Jimenez, Vanessa Carlson, Nidhi J. Kumar Tyagi, Laurence Bernard, Gregory Russell Pond, Lua Ruhiyyih Eiriksson
Publikováno v:
Journal of Clinical Oncology. 40:332-332
e18628 Background: In 2020, ASCO released a Provisional Clinical Opinion recommending universal hepatitis B virus (HBV) screening prior to systemic chemotherapy to reduce the risk of reactivation and associated morbidities. There is limited data for
Autor:
Timothy Joseph Whelan, Sally Smith, Torsten O. Nielsen, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Laval Grimard, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Eileen Rakovitch, Valerie Theberge, Anna Marie Mulligan, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Russell Pond, Mark Norman Levine
Publikováno v:
Journal of Clinical Oncology. 40:LBA501-LBA501
LBA501 Background: Adjuvant breast RT is usually prescribed following BCS to reduce the risk of local recurrence (LR). However, this treatment is inconvenient, costly, and associated with acute and late toxicity. Traditional clinical pathological fac
Publikováno v:
Journal of Clinical Oncology. 40:e21172-e21172
e21172 Background: Outside of clinical trial eligibility criteria, there is limited data to guide the selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) therapy. Chronic obstructive pulmonary disease (
Publikováno v:
Journal of Clinical Oncology. 40:e18017-e18017
e18017 Background: The CheckMate-141 trial led to the approval of nivolumab in platinum-resistant metastatic squamous cell carcinomas of the head and neck (SCCHN). We evaluated outcomes of SCCHN patients in Ontario, Canada treated with nivolumab sinc